Table 2.
Medications That Have Undergone Formal Reviewa
| Alemtuzumab | Nelarabine |
| Alglucosidase alfa | Obinutuzumab |
| Belimumab | Obizur |
| Bendamustine (3) | Octreotide LAR |
| Bevacizumab (4) | Palifermin |
| Blinatumomab | Panhematin (3) |
| Bortezomib | Pegfilgrastim |
| Daratumumab | Pertuzumab |
| Defibrotide | Plerixafor (4) |
| Eculizumab (7) | Rituximab (10) |
| Factor VIIa | Romiplostim |
| Feiba | Ruxolitinib |
| Glucarpidase (2) | Siltuximab (7) |
| Hemin | Teduglutide |
| Infliximab (8) | Tocilizumab (10) |
| IVIG (3) | Trastuzumab |
| Liposomal doxorubicin | Vedolizumab |
| Natalizumab |
a
All medications had at least 1 review through the end of 2016. The number in parentheses indicates the number of requests the medication had for a formal review and approval.
IVIG indicates intravenous immunoglobulin therapy; LA, long-acting.